Infliximab significantly decreases serum calprotectin levels in RA patients, as confirmed by immunohistochemical staining for S100A8 on serial synovium sections, which showed a progressive decrease in the number of infiltrating S100 A9-positive macrophages. The gene discussed is S100A8; the disease is rheumatoid arthritis.